DNER and primary cutaneous T-cell non-Hodgkin lymphoma: BET inhibitors like ABBV-075, when combined with venetoclax, demonstrate promising outcomes in patients with cutaneous T cell lymphoma (CTCL) (Kim et al., 2018).